Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER OLE: Adalimumab in Hidradenitis Suppurativa
NCT01635764Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2012
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc. Primary endpoints: Hidradenitis Suppurativa Clinical Response at 216 weeks, Abscess and Inflammatory Nodule Count 0, 1, or 2 at 216 weeks and 2 more. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT01635764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01635764.